ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 9.2
(5.75%)
CNY 9.2
(5.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 501.67 Million CNY | -14.33% |
| 2022 | 590.06 Million CNY | -9.68% |
| 2021 | 653.3 Million CNY | -13.13% |
| 2020 | 752.05 Million CNY | -12.66% |
| 2019 | 861.04 Million CNY | 5.28% |
| 2018 | 817.83 Million CNY | 35.63% |
| 2017 | 602.97 Million CNY | 34.89% |
| 2016 | 447 Million CNY | 7.39% |
| 2015 | 416.24 Million CNY | 6.71% |
| 2014 | 390.07 Million CNY | 36.23% |
| 2013 | 286.33 Million CNY | 48.92% |
| 2012 | 192.27 Million CNY | 90.95% |
| 2011 | 100.69 Million CNY | 9.7% |
| 2010 | 91.79 Million CNY | 58.17% |
| 2009 | 58.03 Million CNY | -0.81% |
| 2008 | 58.5 Million CNY | 0.0% |
| 2007 | 58.5 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 118.05 Million CNY | 1.1% |
| 2024 Q1 | 104.53 Million CNY | -23.88% |
| 2024 Q2 | 118.73 Million CNY | 13.59% |
| 2023 Q4 | 137.33 Million CNY | 10.05% |
| 2023 FY | 505.5 Million CNY | -14.33% |
| 2023 Q2 | 131.07 Million CNY | 16.71% |
| 2023 Q3 | 124.79 Million CNY | -4.79% |
| 2023 Q1 | 112.3 Million CNY | -28.06% |
| 2022 Q1 | 134.09 Million CNY | -22.22% |
| 2022 Q4 | 156.1 Million CNY | 5.8% |
| 2022 FY | 590.06 Million CNY | -9.68% |
| 2022 Q3 | 147.54 Million CNY | -3.13% |
| 2022 Q2 | 152.31 Million CNY | 13.58% |
| 2021 FY | 653.3 Million CNY | -13.13% |
| 2021 Q1 | 143.86 Million CNY | -35.94% |
| 2021 Q2 | 162.41 Million CNY | 12.9% |
| 2021 Q3 | 174.61 Million CNY | 7.51% |
| 2021 Q4 | 172.4 Million CNY | -1.26% |
| 2020 Q4 | 224.57 Million CNY | 22.75% |
| 2020 FY | 752.05 Million CNY | -12.66% |
| 2020 Q1 | 137.85 Million CNY | -39.6% |
| 2020 Q2 | 206.66 Million CNY | 49.91% |
| 2020 Q3 | 182.95 Million CNY | -11.47% |
| 2019 FY | 861.04 Million CNY | 5.28% |
| 2019 Q4 | 228.23 Million CNY | -3.96% |
| 2019 Q3 | 237.63 Million CNY | 7.79% |
| 2019 Q2 | 220.45 Million CNY | 26.18% |
| 2019 Q1 | 174.72 Million CNY | -23.13% |
| 2018 Q4 | 227.29 Million CNY | 8.28% |
| 2018 Q3 | 209.91 Million CNY | 9.58% |
| 2018 FY | 817.83 Million CNY | 35.63% |
| 2018 Q1 | 189.07 Million CNY | -4.25% |
| 2018 Q2 | 191.55 Million CNY | 1.32% |
| 2017 Q3 | 167.99 Million CNY | 24.9% |
| 2017 Q4 | 197.46 Million CNY | 17.54% |
| 2017 FY | 602.97 Million CNY | 34.89% |
| 2017 Q1 | 103.01 Million CNY | -27.81% |
| 2017 Q2 | 134.5 Million CNY | 30.57% |
| 2016 FY | 447 Million CNY | 7.39% |
| 2016 Q4 | 142.68 Million CNY | 25.05% |
| 2016 Q3 | 114.1 Million CNY | 7.44% |
| 2016 Q2 | 106.2 Million CNY | 26.43% |
| 2016 Q1 | 84 Million CNY | -42.24% |
| 2015 Q4 | 145.44 Million CNY | 50.36% |
| 2015 FY | 416.24 Million CNY | 6.71% |
| 2015 Q1 | 76.67 Million CNY | -38.1% |
| 2015 Q2 | 97.39 Million CNY | 27.03% |
| 2015 Q3 | 96.73 Million CNY | -0.68% |
| 2014 Q3 | 95.5 Million CNY | -0.2% |
| 2014 FY | 390.07 Million CNY | 36.23% |
| 2014 Q1 | 75.01 Million CNY | -29.53% |
| 2014 Q2 | 95.69 Million CNY | 27.57% |
| 2014 Q4 | 123.86 Million CNY | 29.7% |
| 2013 Q4 | 106.44 Million CNY | 70.39% |
| 2013 FY | 286.33 Million CNY | 48.92% |
| 2013 Q1 | 56.63 Million CNY | -10.37% |
| 2013 Q2 | 60.78 Million CNY | 7.32% |
| 2013 Q3 | 62.47 Million CNY | 2.77% |
| 2012 Q4 | 63.19 Million CNY | 16.86% |
| 2012 FY | 192.27 Million CNY | 90.95% |
| 2012 Q2 | 49.1 Million CNY | 89.49% |
| 2012 Q3 | 54.07 Million CNY | 10.13% |
| 2012 Q1 | 25.91 Million CNY | 3.16% |
| 2011 Q2 | 26.49 Million CNY | 19.02% |
| 2011 Q1 | 22.26 Million CNY | -11.05% |
| 2011 FY | 100.69 Million CNY | 9.7% |
| 2011 Q4 | 25.11 Million CNY | -6.33% |
| 2011 Q3 | 26.81 Million CNY | 1.2% |
| 2010 Q4 | 25.02 Million CNY | -0.19% |
| 2010 Q3 | 25.07 Million CNY | 0.0% |
| 2010 FY | 91.79 Million CNY | 58.17% |
| 2009 FY | 58.03 Million CNY | -0.81% |
| 2008 FY | 58.5 Million CNY | 0.0% |
| 2007 FY | 58.5 Million CNY | 0.0% |